IL13 and neoplasm: Furthermore, IFN‐α suppresses the M2 phenotype of TAM induced by IL‐13, making a decline in M2 markers and a significant rise in M1 markers and neutralizing the positive function on proliferation and invasion of HCC cells, and as a result, IFN‐α acts as an adjuvant therapy to sorafenib to develop its anti‐tumor capacity.41